At a glance: Echinacea is not one medicinal product. Several Echinacea species are used, different products may contain root or flowering aerial parts, and preparations range from fresh expressed juice to dry and liquid extracts. Modern research is concentrated on respiratory infections, particularly the common cold. Current evidence suggests some echinacea preparations may slightly reduce the chance of developing a cold, but whether they reliably shorten an established cold remains uncertain.[1][2]
Botanical profile
- Species covered here: principally Echinacea purpurea (L.) Moench.
- Common names: purple coneflower, echinacea.
- Family: Asteraceae.
- Medicinal parts: flowering aerial parts and root are assessed separately.
- EMA herbal drug names: Echinaceae purpureae herba and Echinaceae purpureae radix.[2][3]
Other medicinally used species include Echinacea angustifolia and Echinacea pallida. Their chemistry and preparations are not identical to E. purpurea, so a study on one species should not automatically be cited as evidence for another.[4]
Identification and morphology
Echinacea purpurea is a herbaceous perennial with rough, often lanceolate to ovate leaves and conspicuous composite flower heads. Purple to pink ray florets surround a raised, spiny central cone. The characteristic cone gives the genus its name, derived from the Greek word for hedgehog.
Major constituent groups
Echinacea chemistry varies substantially by species, plant part and extraction method. Important constituent groups include:
- Alkamides, particularly prominent in lipophilic extracts and roots.
- Caffeic-acid derivatives, including cichoric acid in E. purpurea and species-specific phenolic profiles.
- Polysaccharides and glycoproteins, especially in aqueous fractions.
- Polyacetylenes and volatile constituents in some species and preparations.[4][5]
This variation is not a technical footnote. An alcohol-rich root extract can emphasise different constituents from fresh expressed aerial-part juice. Pooling them as though they were one intervention can obscure genuine differences in effect.
Traditional use
Echinacea species have a history of use in North American Indigenous and later eclectic herbal traditions. Preparations were used for bites, stings, wounds, sore throats and infections, and later became widely used in Western herbal practice during colds and other upper-respiratory illnesses. Roots and flowering aerial parts have both been used, depending on species and tradition.
Contemporary herbal practice
In contemporary Western herbal practice, echinacea is most often used around acute upper-respiratory and throat infections and in formulas where local tissue infection or poor resolution is part of the picture. Practitioners distinguish root from flowering aerial parts and may choose different preparations accordingly. It is commonly combined with herbs such as elderflower, thyme or liquorice according to the presentation rather than treated as a generic “immune booster”.
EMA regulatory assessment
The European Medicines Agency assesses fresh flowering aerial parts and root separately. Its monograph on E. purpurea fresh herb covers preparations made from expressed juice of the fresh flowering aerial parts, while a separate monograph covers the root.[2][3]
This separation is an excellent example of preparation-specific herbal regulation. “Echinacea” on a label is not enough information for a rigorous evidence appraisal.
The common cold: what does the clinical evidence say?
Echinacea has been studied extensively for prevention and treatment of upper respiratory tract infections. NCCIH currently concludes that taking echinacea may slightly reduce the chance of catching a cold, but it remains unclear whether it reliably shortens the duration of a cold once one has started.[1]
An influential 2007 meta-analysis reported reductions in the odds of developing a common cold and in cold duration across the trials it pooled. However, the included studies used different species, plant parts, formulations and dosing regimens, creating substantial heterogeneity.[6]
That older positive result should therefore be read alongside later assessments rather than quoted as a universal effect size for every echinacea product.
Why trial results conflict
Several factors make echinacea unusually difficult to study as a single intervention:
- Different Echinacea species may be used.
- Root and aerial parts have different chemical profiles.
- Fresh juice, tinctures, dried extracts and multi-herb mixtures are not equivalent.
- Products may vary in concentrations of alkamides and caffeic-acid derivatives.
- Trials define “prevention”, “treatment” and respiratory infections differently.
- Quality control of commercial products has historically been inconsistent.[4]
Pharmacology and immunology
Laboratory and preclinical research has explored effects of echinacea preparations on immune signalling, macrophage activity, cytokine responses and viral or bacterial systems. Alkamides, caffeic-acid derivatives and high-molecular-weight polysaccharide fractions have all been investigated.[5][7]
Terms such as “immune stimulant” are often too crude. Immune responses are networks rather than a single dial that can simply be turned up. Demonstrating a change in a cytokine or immune-cell assay does not establish that a product prevents infection in people.
Preparations
Medicinal and commercial preparations include:
- fresh expressed juice from flowering aerial parts;
- dry extracts;
- liquid extracts and tinctures;
- root preparations; and
- multi-herb combination products.
When reading a trial, record the species, plant part, extraction solvent, fresh-versus-dried status and whether the product contains other herbs. Without those details, “echinacea” is an incomplete description of the intervention.
Safety
Short-term use of many E. purpurea products appears to be tolerated by most adults. Common adverse effects are gastrointestinal, including abdominal discomfort and nausea. Allergic reactions can occur and may occasionally be severe.[1]
Because echinacea belongs to the Asteraceae family, particular care is sensible in people with a history of allergy to related plants such as ragweed, chrysanthemums, marigolds and daisies.
Children
NCCIH notes that short-term use of some E. purpurea extracts may be tolerated in children, but rashes and potentially significant allergic reactions have occurred in clinical research. Paediatric use should therefore not be inferred from adult supplement labels.[1]
Interactions
Evidence for clinically important drug interactions is less clear-cut than for herbs such as St John’s wort. NCCIH describes conflicting evidence about interactions with some medicines metabolised by the liver and notes theoretical concerns with immunosuppressants and caffeine.[1]
For students, this is a useful distinction: theoretical interaction, pharmacokinetic signal and documented clinical interaction are not interchangeable labels.
Pregnancy and breastfeeding
Limited data exist. NCCIH notes that some studies of E. purpurea and E. angustifolia extracts suggest short-term use may be tolerated early in pregnancy, but advises consultation because evidence remains incomplete; little is known about breastfeeding safety.[1]
Student note: common evidence traps
- Never cite “echinacea” without checking the species.
- Record whether the study used root, fresh aerial parts or another preparation.
- Do not convert an in-vitro immune effect into a clinical infection-prevention claim.
- Older meta-analyses may pool materially different echinacea products.
- Do not paraphrase “may slightly reduce the chance of catching a cold” as “prevents colds”.
- Check whether a study uses a combination product before attributing the effect to echinacea alone.
References
- National Center for Complementary and Integrative Health. Echinacea: Usefulness and Safety. NCCIH. Consulted September 2026.
- European Medicines Agency, Committee on Herbal Medicinal Products. Echinaceae purpureae herba — Echinacea purpurea (L.) Moench., herba recens. EU herbal monograph and assessment documents. EMA. Revision 1 published 2015; periodic-review data call completed 2024.
- European Medicines Agency, Committee on Herbal Medicinal Products. Echinaceae purpureae radix — Echinacea purpurea (L.) Moench., radix. EU herbal monograph and assessment documents. EMA. Revision 1 published 2017; periodic-review data call completed 2024.
- Barnes J, Anderson LA, Gibbons S, Phillipson JD. Echinacea species: a review of their chemistry, pharmacology and clinical properties. Journal of Pharmacy and Pharmacology. 2005;57(8):929–954. doi:10.1211/0022357056127. PubMed.
- Manayi A, Vazirian M, Saeidnia S. Echinacea purpurea: pharmacology, phytochemistry and analysis methods. Pharmacognosy Reviews. 2015;9(17):63–72. PubMed.
- Shah SA, Sander S, White CM, Rinaldi M, Coleman CI. Evaluation of echinacea for the prevention and treatment of the common cold: a meta-analysis. Lancet Infectious Diseases. 2007;7(7):473–480. doi:10.1016/S1473-3099(07)70160-3. PubMed.
- Review of phytochemistry and preclinical immune-response research in echinacea extracts. Antibiotics. 2024;13(10):947. PubMed.
Additional materia medica sources
- ESCOP. Echinaceae purpureae herba and Echinaceae purpureae radix, ESCOP Monographs.
- Blumenthal M, et al., eds. The Complete German Commission E Monographs. American Botanical Council; 1998.
- Mills S, Bone K. Principles and Practice of Phytotherapy. 2nd ed. Elsevier; 2013.
- Hoffmann D. Medical Herbalism. Healing Arts Press; 2003.
Last reviewed: 20 September 2026. Educational reference only; not an individual dosing or prescribing guide.
← Return to the Herbal Monograph Library | Herbal Medicine Safety and Interactions